Bio-Techne (TECH) Income from Non-Controlling Interests (2011 - 2023)
Bio-Techne's (TECH) quarterly Income from Non-Controlling Interests came in at -$212000.0 in Q2 2023, down 102.29% year-on-year from $9.3 million in Q2 2022, and down 200.0% quarter-over-quarter from $212000.0 in Q4 2022.
Bio-Techne (TECH) Income from Non-Controlling Interests (2011 - 2023) Analysis & Trends
Bio-Techne's Income from Non-Controlling Interests history runs 10 years deep, the most recent figure standing at -$212000.0 for Q2 2023.
- On a quarterly basis, Income from Non-Controlling Interests fell 102.29% year-over-year to -$212000.0 in Q2 2023; TTM through Jun 2023 was -$33000.0, a 100.38% decrease from a year earlier, with the FY2023 full-year figure at -$33000.0, up 52.86% from the prior year.
- Income from Non-Controlling Interests fell to -$212000.0 in Q2 2023 per TECH's latest filing, from $212000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $9.3 million in Q2 2022 and bottomed at -$634000.0 in Q3 2021.
- The 4-year median for Income from Non-Controlling Interests is $32500.0 (2021), against an average of $846300.0.
- Across the five-year window, Income from Non-Controlling Interests jumped 10319.1% in 2022 and sank 102.29% in 2023, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at $83000.0 in 2020, then retreated by 20.48% to $66000.0 in 2021, then surged by 221.21% to $212000.0 in 2022, then sank by 200.0% to -$212000.0 in 2023.
- Per Business Quant, the three latest TECH Income from Non-Controlling Interests figures stand at -$212000.0 (Q2 2023), $212000.0 (Q4 2022), and -$33000.0 (Q3 2022).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Bio-Techne | 11.23 Bn | 11.02 Bn | 208.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -212,000.00 |
| Dec 31, 2022 | 212,000.00 |
| Sep 30, 2022 | -33,000.00 |
| Jun 30, 2022 | 9.27 Mn |
| Mar 31, 2022 | -1,000.00 |
| Dec 31, 2021 | 66,000.00 |
| Sep 30, 2021 | -634,000.00 |
| Jun 30, 2021 | 89,000.00 |
| Mar 31, 2021 | -380,000.00 |
| Dec 31, 2020 | 83,000.00 |
| Mar 31, 2016 | -32.08 Mn |
| Dec 31, 2015 | 9.60 Mn |
| Sep 30, 2015 | -10.13 Mn |
| Jun 30, 2015 | 2.51 Mn |
| Mar 31, 2015 | 2.95 Mn |
| Dec 31, 2014 | 14.34 Mn |
| Sep 30, 2014 | -8.49 Mn |
| Jun 30, 2014 | -5.32 Mn |
| Mar 31, 2014 | 5.31 Mn |
| Dec 31, 2013 | 1.02 Mn |